Latest Press Releases
Former UFC Middleweight Champion to join Xycota Chief Scientific Officer Marvin S. Hausman, M.D., for an upcoming podcast examining repeated head impact, PTSD, and sub-perceptual psilocybin research targeting brain-repair pathways.
- Public Science Dialogue: UFC Hall of Famer Michael Bisping and Xycota Co-Founder and CSO Marvin S. Hausman, M.D., plan to record a public podcast on concussion, mild traumatic brain injury (mTBI), and mild PTSD.
- Sub-Perceptual Psilocybin Thesis: Xycota is investigating whether low-dose psilocybin can engage the brain's BDNF/TrkB neuroplasticity pathway at home without hallucinogenic effects.
- Preclinical and Corporate Status: All Xycota candidates remain preclinical and unapproved; BioAdaptives, Inc.'s (OTCID: BDPT) agreement to acquire Xycota remains subject to closing conditions.
Zero-login digital companion offers immediate breathing resets and vetted trauma support today, while Xycota prepares preclinical BDNF/TrkB psilocybin research for practical outpatient care.
- Free, Off-Record PTSD Support Available Today: Live at https://xycota.com/ptsd, the free hub requires no account or cloud data storage and offers guided 60-second physiological sigh, box breathing, and 5-4-3-2-1 sensory grounding tools, a private browser-only log, and a confidential support matcher for veterans, first responders, and families.
- Sub-Perceptual, At-Home Psilocybin Research (XYCO-02): Alongside free community tools, Xycota is preparing a Canadian clinical trial application with KGK Science to test whether low-dose oral psilocybin can engage the brain's BDNF/TrkB repair pathway at home without a six-to-eight-hour clinic trip.
- Two-Company Structure and Shareholder Safeguards: BioAdaptives, Inc.'s (OTCID:BDPT) definitive agreement to acquire Xycota keeps biotech and nutraceutical operations separate, includes conditional funding for a proposed nutraceutical spin-off, and enforces a 12-month founder lock-up and daily note resale limits.
Xycota's lead program aims to deliver clinical benefit from low-dose psilocybin without hallucinogenic effects, with mild PTSD as its initial target.
UFC Hall of Famer and MyndSystem™ brand ambassador shares how the daytime formula fits into his preparation for live broadcasts, commentary, and podcasting.
Initial XcellaraHeart™ orders ship next week, marking the commercial launch of the Xcellara™ cellular wellness platform; Company prepares XcellaraResilience™ for October launch and highlights the retirement of major convertible debt and 43.25M insider shares.
Former UFC middleweight champion and current broadcaster will help promote MyndSystem™ as part of a disciplined day-and-night performance routine
Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure.
The flagship product of the new Xcellara™ cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating stem cells after 4 weeks.
The Platform integrates clinically researched stem and progenitor cell mobilization with ingredients that have been studied for their roles in tissue signaling pathways.
Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform